Vectorbuilder Inc

Activities: Research & Development

Revolutionise gene delivery from research to therapy

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. TerraCycle launches BlisterBack solution to increase medicine blister pack recycling The initiative allows the collection and recycling of medicine blister packs, which would otherwise end up in landfill
  3. Brainomix receives FDA clearance of e-Lung AI software The software allows healthcare professionals to assess the condition of a patient with interstitial lung disease using AI technology
  4. Amgen's Imdelltra receives US FDA approval for extensive-stage SCLC Imdelltra received approval following the positive results of the Phase II DeLLphi-301 clinical trial
  5. Sartorius collaborate with NVIDIA to advance manufacturing with AI The collaboration will aim to enhance research and development, as well as manufacturing protocols using artificial intelligence (AI)

Upcoming event

BIO International Convention Digital

3-6 June, 2024 | Convention | San Diego, US See all

Related Content

Manufacturing

Why has gene delivery become such a hot property?

VectorBuilder's latest cash injection drives them towards a CDMO facility for the manufacturing of plasmids, mRNA, AAV, lentivirus, cell lines, and a variety of viral and non-viral vectors
Manufacturing

Plasmid and lentiviral vector CDMO VectorBuilder orders rise by 70%

The company's plasmid and lentiviral vector CDMO products have received Investigational New Drug (IND) approval from the FDA
Research & Development

VectorBuilder to construct R&D and manufacturing campus

Construction is expected to cost $500m and will be split into two phases over the next four years
Subscribe now